Dovepress 23. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340(24): 1888–1899. 24. Smalley WE, Griffin MR, Fought RL, Ray WA. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med. 1996;11(8):461–469. 25. Fendrick AM, Scheiman JM. Decision analytic modeling and NSAID gastropathy: Could we be more sensitive? J Gen Intern Med. 2000;15(6):430–431. 26. Cross PL, Ashby D, Harding G, et al. Are topical or oral ibuprofen equally effective for the treatment of chronic knee pain presenting in primary care: A randomized controlled trial with patient preference study. BMC Musculoskelet Disord. 2005;6:55. 27. Castelnuovo E, Cross P, Mt-Isa S, Spencer A, Underwood M; on behalf of the TOIB study team. Cost-effectiveness of advising the use of topi- cal or oral ibuprofen for knee pain; the TOIB study. Rheumatology (Oxford). 2008;47(7):1077–1081. 28. Rahme E, Barkun AN, Adam V, Bardou M. Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs. Drug Saf. 2004;27(13):1019–1042. 29. Massó González EL, Pastrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62(6):1592–1601. 30. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. BMJ. 2002;325(7365):619. 31. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoar- thritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247–1255. 32. Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002;167(10):1131–1137. 33. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associ- ated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–959. 34. Farkouh ME, Greenberg BP. An evidence-based review of the cardio- vascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009;103(9):1227–1237. 35. Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflam- matory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59(8):1097–1104. 36. American Geriatrics Society Panel on the Pharmacological Manage- ment of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8): 1331–1346. 37. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3): 728–738. 38. American Academy of Orthopaedic Surgeons. Treatment of Osteoar- thritis of the Knee (Non-Arthoplasty) Full Guideline. Rosemont, IL: American Academy of Orthopedic Surgeons; 2008. 39. Moore RA, Derry S, McQuay HJ. Topical agents in the treatment of rheumatic pain. Rheum Dis Clin North Am. 2008;34(2):415–432. Nonsteroidal anti-inflammatory drug gastropathy 40. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(13):238–245. 41. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topi- cal diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. J Rheumatol. 2004;31(10):2002–2012. 42. Altman R, Barkin RL. Topical therapy for osteoarthritis: Clinical and pharmacologic perspectives. Postgrad Med. 2009;121(2):139–147. 43. Altman RD. Practical considerations for the pharmacologic management of osteoarthritis. Am J Manag Care. 2009;15(8 Suppl):S236–S243. 44. Roth SH. Salicylates revisited. Are they still the hallmark of anti- inflammatory therapy? Drugs. 1988;36(1):1–6. 45. Carnes D, Anwer Y, Underwood M, Harding G, Parsons S; TOIB Study Team. Influences on older people’s decision making regarding choice of topical or oral NSAIDs for knee pain: Qualitative study. BMJ. 2008; 336(7636):142–145. 46. Makris UE, Kohler MJ, Fraenkel L. Adverse effects of topical non- steroidal anti-inflammatory drugs in older adults with osteoarthritis: A systematic literature review. J Rheumatol. 2010;37(6):1236–1243. 47. Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: A randomized controlled trial. CMAJ. 2004;171(4):333–338. 48. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (PENNSAID) in the treatment of primary osteoarthritis of the knee: A randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med. 2004;164(18):2017–2023. 49. Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: A randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord. 2005; 6:44. 50. Niethard FU, Gold MS, Solomon GS, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol. 2005; 32(12):2384–2392. 51. Barthel HR, Haselwood D, Longley S 3rd, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum. 2009;39(3):203–212. 52. Baraf HS, Gold MS, Clark MB, et al. Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: A randomized con- trolled trial. Phys Sportsmed. 2010;38(2):19–28. 53. Voltaren Gel (diclofenac sodium topical gel) 1% [prescribing information]. Chadds Ford, PA: Endo Pharmaceuticals Inc. 54. Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symp- tomatic knee osteoarthritis. Arthritis Rheum. 2008;59(9):1207–1213. 55. Viviane AV, Alan BN. Estimates of costs of hospital say for variceal and nonvariceal upper gastrointestinal bleeding in the United States. Value Health. 2008;11(1):1–3. 56. Niculescu L, Li C, Huang J, Mallen S. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2009;25(3):729–740. 57. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and meta-analysis of information from com- pany clinical trial reports. Arthritis Res Ther. 2005;7(3): R644–R645. Clinical Interventions in Aging Publish your work in this journal Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine, the American Chemical Society’s ‘Chemical Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal Dovepress Abstracts Service’ (CAS), Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors. Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com Dovepress 131